Polymerization Induced Self-Assembly of a Site-Specific Interferon α-Block Copolymer Conjugate into Micelles with Remarkably Enhanced Pharmacology

被引:84
作者
Liu, Xinyu [1 ]
Sun, Mengmeng [1 ]
Sun, Jiawei [1 ]
Hu, Jin [1 ]
Wang, Zhuoran [1 ]
Guo, Jianwen [1 ]
Gao, Weiping [1 ]
机构
[1] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China
基金
中国国家自然科学基金;
关键词
AQUEOUS DISPERSION POLYMERIZATION; TRANSFER RADICAL POLYMERIZATION; CHRONIC HEPATITIS-C; I INTERFERONS; PROTEIN; PHARMACOKINETICS; GROWTH; TERMINUS; EFFICACY; PEGASYS;
D O I
10.1021/jacs.8b06013
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Conjugating a hydrophilic and protein-resistant polymer to a protein is a widely used strategy to extend the in vivo half-life of the protein; however, the benefit of the half-life extension is usually limited by the bioactivity decrease. Herein we report a supramolecular self-assembly strategy of site-specific in situ polymerization induced self-assembly (SI-PISA) to address the dilemma. An amphiphilic block copolymer (POEGMA-PHPMA) was directly grown from the C-terminus of an important therapeutic protein interferon-alpha (IFN) to in situ form IFN-POEGMA-PHPMA conjugate micelles. Notably, the in vitro bioactivity of the micelles was 21.5-fold higher than that of the FDA-approved PEGylated interferon-alpha PEGASYS. Particularly, the in vivo half-life of the micelles (83.8 h) was 1.7- and 100-fold longer than those of PEGASYS (49.5 h) and IFN (0.8 h), respectively. In a tumor-bearing mouse model, the micelles completely suppressed tumor growth with 100% animal survival, whereas at the same dose, PEGASYS and IFN were much less effective. These findings suggest that SI-PISA is promising as a next-generation technology to remarkably enhance the pharmacological performance of therapeutic proteins with short circulation half-lives.
引用
收藏
页码:10435 / 10438
页数:4
相关论文
共 32 条
[1]   FDA-approved poly(ethylene glycol)-protein conjugate drugs [J].
Alconcel, Steevens N. S. ;
Baas, Arnold S. ;
Maynard, Heather D. .
POLYMER CHEMISTRY, 2011, 2 (07) :1442-1448
[2]  
Algranati NE, 1999, HEPATOLOGY, V30, p190A
[3]   Synthesis of poly(2-hydroxypropyl methacrylate) latex particles via aqueous dispersion polymerization [J].
Ali, A. M. I. ;
Pareek, P. ;
Sewell, L. ;
Schmid, A. ;
Fujii, S. ;
Armes, S. P. ;
Shirley, I. M. .
SOFT MATTER, 2007, 3 (08) :1003-1013
[4]   Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-α protein therapeutic [J].
Bell, Stacie J. ;
Fam, Christine M. ;
Chlipala, Elizabeth A. ;
Carlson, Sharon J. ;
Lee, Ji I. ;
Rosendahl, Mary S. ;
Doherty, Daniel H. ;
Cox, George N. .
BIOCONJUGATE CHEMISTRY, 2008, 19 (01) :299-305
[5]   Treating cancer with PEG intron - Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation [J].
Bukowski, RM ;
Tendler, C ;
Cutler, D ;
Rose, E ;
Laughlin, MM ;
Statkevich, P .
CANCER, 2002, 95 (02) :389-396
[6]   Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS) [J].
Foser, S ;
Schacher, A ;
Weyer, KA ;
Brugger, D ;
Dietel, E ;
Marti, S ;
Schreitmüller, T .
PROTEIN EXPRESSION AND PURIFICATION, 2003, 30 (01) :78-87
[7]   In Vitro and In Vivo Preclinical Effects of Type I IFNs on Gliomas [J].
Galani, Vasiliki ;
Papadatos, Stamatis S. ;
Alexiou, George ;
Galani, Angeliki ;
Kyritsis, Athanasios P. .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2017, 37 (04) :139-146
[8]   In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation [J].
Gao, Weiping ;
Liu, Wenge ;
Christensen, Trine ;
Zalutsky, Michael R. ;
Chilkoti, Ashutosh .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (38) :16432-16437
[9]   In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics [J].
Gao, Weiping ;
Liu, Wenge ;
Mackay, J. Andrew ;
Zalutsky, Michael R. ;
Toone, Eric J. ;
Chilkoti, Ashutosh .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (36) :15231-15236
[10]   A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C [J].
Glue, P ;
Rouzier-Panis, R ;
Raffanel, C ;
Sabo, R ;
Gupta, SK ;
Salfi, M ;
Jacobs, S ;
Clement, RP .
HEPATOLOGY, 2000, 32 (03) :647-653